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Abstract
Genome-wide association studies (GWAS) in several populations have demonstrated significant association of the IL23R
gene with IBD (Crohn’s disease (CD) and ulcerative colitis (UC)) and psoriasis, suggesting that perturbation of the IL-23
signaling pathway is relevant to the pathophysiology of these diseases. One particular variant, R381Q (rs11209026), confers
strong protection against development of CD. We investigated the effects of this variant in primary T cells from healthy
donors carrying IL23R
R381 and IL23R
Q381 haplotypes. Using a proprietary anti-IL23R antibody, ELISA, flow cytometry,
phosphoflow and real-time RT-PCR methods, we examined IL23R expression and STAT3 phosphorylation and activation in
response to IL-23. IL23R
Q381 was associated with reduced STAT3 phosphorylation upon stimulation with IL-23 and
decreased number of IL-23 responsive T-cells. We also observed slightly reduced levels of proinflammatory cytokine
secretion in IL23R
Q381 positive donors. Our study shows conclusively that IL23R
Q381 is a loss-of-function allele, further
strengthening the implication from GWAS results that the IL-23 pathway is pathogenic in human disease. This data provides
an explanation for the protective role of R381Q in CD and may lead to the development of improved therapeutics for
autoimmune disorders like CD.
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Introduction
The inflammatory bowel diseases (IBD), Crohn’s disease (CD)
and ulcerative colitis (UC), have long been recognized as having a
genetic element to disease susceptibility [1,2]. Following the
discovery of NOD2 as a CD susceptibility gene, there have been
over seventy susceptibility genes and loci implicated in IBD [3],
especially with the advent of genome-wide association studies.
These newly discovered genetic associations have shed light on the
biological pathways involved in disease initiation and pathogenesis.
Several genes in the Th17 pathway have been linked with IBD
susceptibility, including IL23R, TNFSF15, STAT3, IL12B, CCR6
and JAK2 [3]. Of all the Th17 pathway genes, the interleukin 23
receptor (IL23R) gene (GenBank accession: NM_144701, GeneID:
149233) on chromosome 1p31 confers the highest odds-ratio (OR)
for disease development/lowest OR for disease protection [4,5,
6,7,8,9,10,11,12], as well as being implicated in other chronic
inflammatory diseases including psoriasis [13] and ankylosing
spondylitis [14]. R381Q (rs11209026), the only coding IL23R
variant identified by GWAS, confers an OR of 0.45 for Crohn’s
disease development (MAF 1.9% in CD, 7% in controls) [4], and
an OR of 0.55 for UC development (MAF 3.7% in UC, 7% in
controls) [15], implying a protective effect.
IL23R is most highly expressed on activated T cells, particularly
of the Th17 subtype, natural killer (NK) cells and at lower levels on
monocytes, macrophages and dendritic cells [16].
IL23R pairs with IL12RB1 to confer IL-23 responsiveness on
cells expressing both receptor subunits [16,17]. Upon activation by
IL-23, IL23R signals through the JAK/STAT pathway. IL23R
associates constitutively with JAK2 and, in a ligand-dependent
manner, with STAT3, STAT1, STAT4 and STAT5 can also be
activated by IL-23 [16]. On ligand binding, JAK2 phosphorylates
IL23R at Tyr705, recruiting STAT3 to the receptor complex,
where it is further phosphorylated by JAK2. Phosphorylated
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25038STAT3 homodimerizes and translocates to the nucleus where it
triggers downstream expression of cytokines, including IL-17A, IL-
17F, IL-22 and IL-21 in Th17 cells (reviewed in [18,19]).
As well as functioning as a mediator of cytokine production in
Th17 pathway cells, several studies also suggest that IL23R is a key
player in the proliferation and survival of Th17 cells [17,20,21].
Studies in intestinal tissue have shown that IL-17F and IL-22
mRNA expression (induced via IL-23 signaling) are significantly
increased in inflamed colonic lesions in CD compared to
uninflamed biopsies, and that IL-22 is associated with a higher
expression of inflammatory mediators [22,23].
Because of its role in T cell biology and the compelling genetic
evidence, we hypothesized that IL23R
Q381 could potentially
influence the response of the IL23R-expressing cells such as
Th17 cells in the host. Indeed, a recent study by Di Meglio and
colleagues [24] suggests that IL23R
Q381 exerts its protective effects
through attenuation of IL-23 induced Th17 function.
We investigated this possibility using primary T cells from
healthy donors carrying IL23R
R381 and IL23R
Q381 haplotypes.
Results
Arginine 381 is absolutely conserved across different
species
The R381Q polymorphism is located between the transmem-
brane domain and the putative JAK2 binding site in the
cytoplasmic portion of IL23R protein, and is absolutely conserved
across different species (Fig. 1 A, B). By virtue of its location, this
polymorphism could potentially interfere with either surface
localization of the IL23R [25] or signal transduction [26]; it is
unlikely to interfere with ligand binding.
Untransformed polyclonal IL23R
Q381 positive T cell lines
have decreased number of IL23R positive cells and
reduced IL-23 responsiveness compared to IL23R
R381 T
cell lines
To study the effects of the R381Q polymorphism we used
untransformed polyclonal T cell lines from donors carrying either
IL23R
R381 or IL23R
Q381. IL23R positive cells were detected using
proprietary monoclonal antibody against human IL23R (Fig. 1S).
We genotyped 138 healthy donors and identified eighteen
IL23R
Q381 heterozygous individuals and one homozygous individ-
ual. The calculated allele frequency of 7.1% of R381Q is consistent
with the published estimates (7.0% [4] 7.3% [27]; 6.0% [28]). We
generated T cell lines from five IL23R
R381, four IL23R
Q381
heterozygous, and one IL23R
Q381 homozygous donors. All donors
were Caucasian of ages 25 to 65.
We observed no obvious differences in viability and prolifera-
tion rates between these T cell lines during in vitro expansion (Fig.
S2A, B). However, flow cytometry analysis performed after six
days of in vitro stimulation with feeder mixture (see Methods),
revealed significantly diminished population of IL23R positive T
cell from IL23R
Q381 positive donors compared to their IL23R
R381
counterparts (Fig. 2A, B). Consistently, when stimulated with IL-
23 we observed fewer pSTAT3 positive cells in IL23R
Q381
samples (Fig. 2C–D). In addition, the median fluorescence
intensity (MFI) of IL-23 stimulated pSTAT3 positive cells was
reduced (Fig. 2E), suggesting that not only was there a specific
reduction of IL-23–responsive T-cells generated from IL23R
Q381
positive individuals but also the strength of the IL-23 response for
any given cell was decreased by the R381Q polymorphism.
By comparison, IL-6-elicited STAT3 phosphorylation was unaf-
fected by the IL23R genotype, demonstrating that IL23R
Q381
positive cells are intrinsically capable of full STAT3 activation
(Fig. 2C, D).
Untransformed polyclonal IL23R
Q381 positive T cell have
decreased IL-23-induced pSTAT1 and pSTAT5 compared
to IL23R
R381 T cell lines
To further characterize this phenomenon, we examined IL-23-
induced STAT1 and STAT5 phosphorylation. To reduce
background levels of STAT5 phosphorylation elicited by endog-
enously produced IL-2, we added a neutralizing monoclonal anti-
human IL-2 antibody to the cultures during IL-23 stimulation. We
observed significantly decreased levels of both STAT5 (Fig. 3A, C)
and STAT1 phosphorylation (Fig. 3B, C) in IL23R
Q381 bearing T
cells compared to the IL-23R
R381 positive lines. The MFI of
pSTAT5 positive cells was slightly decreased and pSTAT1 positive
cells significantly decreased after IL-23 stimulation, in agreement
with the defect observed in STAT3 phosphorylation. On the other
hand, when stimulated with IL-2, pSTAT5 levels were equivalent
between IL23R
R381 and IL23R
Q381 cell lines (Fig. 3A, C).
Figure 1. The arginine at position 381 of the IL23R is absolutely conserved across different species. (A) Map of the IL23R gene. (B)
Sequence alignment of IL23R protein sequences from different species.
doi:10.1371/journal.pone.0025038.g001
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R381 and
IL23R
Q381 donors, we analyzed freshly isolated peripheral blood
mononuclear cells (PBMCs) from the same donors. IL23R
expression is known to be activation dependent [29], and indeed
we could not detect any IL23R expression on freshly isolated
PBMC (data not shown). Therefore, we stimulated total PBMCs
with agonist antibodies directed against CD3 and CD28 for
72 hours and then analyzed IL23R surface expression. After
stimulation, we clearly observed IL23R expression on the
IL23R
R381 T cells, while the IL23R
Q381 T cells had slightly, but
not significantly decreased number of IL23R positive cells (Fig. 4A,
B). We also observed decreased numbers of pSTAT3 positive
IL23R
Q381 CD4
+ cells, compared to IL23R
R381 CD4
+ cells when
we stimulated whole blood with IL-23. IL-6 stimulation resulted in
similar numbers of pSTAT3 positive cells, regardless of IL23R
genotype (Fig. 4C, D), confirming our data from T cell lines.
Peripheral blood cytokine levels are slightly decreased in
IL23R
Q381 positive donors compared to IL23R
R381
To investigate the functional impact of the IL23R
R381Q in terms
of cytokine secretion, we used stimulated T cell lines from
IL23R
R381 and IL23R
Q381 donors to measure the production of
cytokines by intracellular staining (Fig. 5A–C). We observed
slightly, but not significantly decreased levels of IL-17A, IL-22 and
IFN-g in IL23R
Q381 positive donors. Similar results were observed
when fresh PBMCs from IL23R
R381 and IL23R
Q381 positive
donors were stimulated (Fig. S3A–C). Interestingly, a recent
study [30] using primary T cells from IL23R
R381 (n=27) and
IL23R
Q381 (n=13) positive donors showed that IL23R
Q381 donors
have decreased IL-23–dependent IL-17 and IL-22 production.
Serum IL-22 levels were determined using enzyme-linked
immunosorbent assay (ELISA), and we again observed a slight,
but not significant, trend toward decreased IL-22 production in
IL23R
Q381 donors compared to IL23R
R381 donors, in agreement
with previously published data [31]. We also extracted RNA from
fresh PBMCs and analyzed IL23R and RORC (a Th17 marker)
mRNA expression by real-time PCR. We observed heterogeneity
among donors, but no significant differences between IL23R
R381
and IL23R
Q381 positive donor groups (Fig. 5F), which could be
attributed either to the low number of donors or the possibility that
this variant is has no effect on mRNA processing.
Discussion
In the past several years, GWAS have lead to major
breakthroughs in our understanding of the genetics of CD.
However, there have been relatively few published studies
Figure 2. Untransformed polyclonal IL23R
Q381 positive T cell lines have a decreased number of IL23R positive cells and reduced IL-
23 responsiveness compared to IL23R
R381 T cell lines. Flow cytometric analyses of T cell lines from IL23R
R381 and IL23R
Q381 donors is shown.
Numbers in the quadrants indicate percent cells in that quadrant. (A) IL23R cell surface expression on non-permeabilized T cells of representative
donors and (B) the mean percent (n=4) of IL23R positive cells is shown. The error bars indicate standard deviation (SD). IL-23 and IL-6 induced STAT3
phosphorylation in (C) representative donors and (D) 4 donors per group. (E) The MFI pSTAT3 signal in the pSTAT3 positive population (n=4). Data
are representative examples of at least three independent experiments. The Mann-Whitney test was used to calculate the p value.
doi:10.1371/journal.pone.0025038.g002
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32,33]. We chose several relevant in vitro systems to demonstrate
conclusively that the R381Q variant results in decreased
population of IL-23 responsive cells, as well as an attenuation of
signaling via the IL23R, manifesting in diminished IL-23
dependent activation of all STATs known to be associated with
IL-23 signaling. Supporting our results, a recent study [24] using in
vitro polarized Th17 cell from IL23R
R381 (n=22) and IL23R
Q381
(n=19) positive donors demonstrated that the cells from
L23R
Q381 positive donors had impaired IL-23-mediated IL-17A
production and STAT3 phosphorylation.
Several mechanisms might contribute to this observation,
including reduced capacity of IL23R
Q381 to activate STAT proteins
due to impaired association of JAK2 proteins with the cytoplasmic
tail of the receptor. Arginine 381 is located near the JAK2 putative
binding site (Fig. 1). However, in order to determine whether
R381Q is truly a causative variant and not a tagging single
nucleotide polymorphism (SNP), which tags a protective IL23R
haplotype associated with decrease population of IL23R positive/
responsive cells, further studies such as generation of a R381Q
knock-in mouse model would have to be conducted.
One of the major advantages of our study was the availability of
healthy donors willing to donate blood repeatedly for our primary
T cells studies. It should be noted that, while we used T cells in our
analysis, the protective effect of IL23R
Q381 is likely to be co-
mediated by other IL-23 responsive cell types (e.g. dendritic cells
[16]) in vivo). We observed decreases in cytokine levels in
IL23R
Q381 positive donors compared to IL23R
R381 donors in
peripheral blood. However, the difference was not significant,
potentially because of the small number of available samples.
For future studies it will be important to analyze a much larger
cohort of donors. In addition, it will be interesting to conduct deep
sequencing studies to identify additional genetic variants harbored
in IL23R. Indeed, recent study by Monozawa and colleagues [34]
reported a number of low frequency IL23R variants identified by
resequencing of positional candidates.
It is important to note that despite the R381 risk variant having
an allelic frequency of greater than 90% in Caucasian
populations, the prevalence of CD in North American popula-
tions is only approximately 0.2% [35] [36]. This underlies the
polygenic nature of CD susceptibility and the importance of other
genes (e.g. NOD2, ATG16L1) as well as environmental influences
(e.g. smoking, diet and possibly bacteria) on the risk of CD
development.
IL23R is a key player in the proliferation and survival of Th17
cells, which are critical for host defense against bacterial, fungal
and viral infections at mucosal surfaces [37]. Negative evolution-
ary selection to insure an appropriate defense response may
Figure 3. Untransformed polyclonal IL23R
Q381 positive T cell have decreased IL-23 induced pSTAT1 and pSTAT5 compared to
IL23R
R381 T cell lines. (A) IL-23 and IL-2 induced pSTAT5 and (B) IL-23 induced pSTAT1 response in representative donors and (C) the mean of the
percent positive from and MFI of pSTAT1 and pSTAT5 (n=4). Data are representative examples of at least two independent experiments. The Mann-
Whitney test was used to calculate the p value.
doi:10.1371/journal.pone.0025038.g003
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variant.
In summary, our data indicate that IL23R
Q381 is a hypomor-
phic IL23R allele that results in a decreased population of IL-23
responsive cells, leading to diminished IL-23-induced STAT3
phosphorylation. This provides an explanation for the protective
role of R381Q in CD and other autoimmune disorders (Fig. 6) and
further supports the hypothesis that blocking the IL-23 pathway
may lead to improved therapeutics for autoimmune disorders like
CD [38] and psoriasis [39].
Materials and Methods
Antibodies and ELISA
Information for all antibodies used in this study is summarized
in Table S1. A monoclonal antibody against human IL23R (clone
20G3.4) was generated by immunizing mice with a hIL23R-Ig
fusion protein (Fig. 1S).
Biotinylated and FITC-conjugated versions of this antibody
were used in this study. Serum IL-22 levels of human genotype
specific healthy donors were measured using the IL-22 ELISA
MAX Set Deluxe kit (BioLegend, Inc) according to the
manufacturer’s instructions. Human IL-17A levels were mea-
sured in supernatants from PBMCs isolated from genotype
specific healthy donors and stimulated with anti-CD3 (2.5 ug/
ml) and anti-CD28 (1 ug/ml) antibodies+/2IL-23 (5 ng/ml) for
2 days. Supernatants were harvested and analyzed using hIL-
17A ELISA (eBioscience) according to the manufacturer’s
instructions.
IL23R construct
Gateway recombination cloning technology (Invitrogen) was
used to create all constructs. Full-length wild-type IL23R coding
sequence was PCR amplified using following primers: forward 59
GGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGAAT-
CAGGTCACTATT -3 9 (bold - attB1 site; underlined - kozak; italics
- Il23R nucleotides 1–18). Reverse 59 – GGGGACCACTTTG-
TACAAGAAAGCTGGGTCCTACTTTTCCAAGAGTGA -3 9
(bold - attB1 site; underlined - stop; italics - Il23R nucleotides
1872–1886). PCR product was cloned into the pDONR221 donor
vector (Invitrogen, Carlsbad, CA). Construct encoding IL23R
R381
was subsequently transferred into a gateway adapted pMSCVpuro
Figure 4. PBMCs from IL23R
Q381 positive donors have decreased IL23R surface expression and reduced IL-23 responsiveness
compared to IL23R
R381. Flow cytometric analyses of PBMCs from IL23R
R381 and IL23R
Q381 donors is shown. Numbers in the quadrants indicate
percent cells in each. (A) IL23R expression on non-permeabilized PBMCs stimulated with anti-CD3 and anti-CD28 antibodies for 72 hours of
representative donors and (B) the mean of the percent positive from 4 donors per group is shown. The error bars indicate SD. IL-23 and IL-6 induced
STAT3 phosphorylatin in whole blood from (C) representative donors and (D) 4 donors per group. Data are representative examples of at least three
independent experiments. The Mann-Whitney test was used to calculate the p value.
doi:10.1371/journal.pone.0025038.g004
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sequence verified.
BaF3 cell culture and transduction
BaF3 cells [40] were maintained in RPMI supplemented with
10% bovine calf serum, L-Glutamine and Penicillin-Streptomycin
(Invitrogen, Carlsbad, CA). Conditioned medium from WEHI-3B
cells was used as a source of IL-3 and added to the culture at 2%
final concentration. A pMSCV- based plasmid encoding hIL-
12RB1 was introduced by electroporation, and positive single cell
clones were identified and sorted by FACS into individual wells of
96-well plates. Human IL23R
R381 cDNA, cloned in the
pMSCVpuro retroviral expression vector, was introduced into
the same hIL-12RB1 containing BaF3 subclones by standard
retroviral transduction. 293T cells in combination with the
retroviral packaging vector pCL-Eco (Imgenex) were used as a
packaging system. Twenty-four hours after transduction, BaF3
cells were put in 1 mg/ml puromycin (Clontech) medium to select
transduced cells. Relative IL23R and IL12RB1 mRNA abun-
dances were verified by qPCR.
To detect IL23R cell surface expression BaF3 cells were stained
with biotinylated IL23R antibody 20G3.4 in combination with
streptavidin-PE (eBioscience). Isotype control antibodies were used
as negative controls (BD biosciences).
Genotyping
Blood samples were obtained from healthy donors after written
informed consent was provided. Ethical approval for the use of this
material was obtained from the Western Institutional Review
Board. Genomic DNA was isolated from 138 healthy donors, and
Figure 5. Peripheral blood cytokine levels are comparable in IL23R
Q381 and IL23R
R381 positive donors. ICS of cytokine production by T
cell lines stimulated with anti-CD3/ CD28 dynabeads (A) representative donors for IL-22 and IL-17 and (B) IL-10 and INF-g (C) Frequency of cytokine
positive cells (n=4/per group). (D) Cytokine production by PBMCs stimulated with anti-CD3 and anti-CD28 antibodies+/2IL-23 and measured by
ELISA (3 donors per group) (E) Serum IL-22 levels in IL23R
Q381 and IL23R
R381 positive donors (5 donors per group) measured by ELISA. (F) Real-time
PCR analysis for IL23R and RORC mRNA expression, presented (in arbitrary units (AU)) relative to GAPDH expression (used as an internal
‘‘housekeeping’’ control). mRNA collected from PBMCs of IL23R
R381 (5 donors) and IL23R
Q381 (6 donors). Each symbol represents a donor. Data are
representative examples of at least two independent experiments. The Mann-Whitney test was used to calculate the p value.
doi:10.1371/journal.pone.0025038.g005
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Biosystems TaqMan SNP genotyping assay (assay ID: C_1272298_10).
Eighteen donors were identified as being IL23R
Q381 heterozygous
(GA) and 1 homozygous (AA).
T cell lines
T cell lines were generated as previously described [41,42,43].
Briefly, CD4
+ T cells were sorted from whole blood of IL23R
R381
and IL23R
Q381 positive donors using a human whole blood CD4
selection kit (RoboSep; StemCell Technologies) according to the
manufacturer’s instructions (purity of the CD4+ cells after
enrichment was .95%). Cells were seeded at 5610
5 cells/ml
and stimulated with a feeder mixture containing 1610
6/ml
irradiated (6,000 rad) allogenic PBMC and 1610
5/ml irradiated
(10,000 rad) JY cells, 1 mg/ml phytohemagglutinin (Sigma), and
200 IU/ml recombinant human IL-2 (Roche). Cells were cultured
in Yssel’s medium (Gemini Bio-Products) supplemented with 1%
human serum. T cells were restimulated with the feeder mixture
every 2 weeks. Cell surface expression of IL23R was analyzed by
flow cytometry 6 days after stimulation.
T cell culture
PBMCs were isolated from whole blood of IL23R
R381 and
IL23R
Q381 positive donors using UNI-SEP (U-10, Accurate Che-
mical) pre-filled tubes containinga solution of 5.6% polysucrose and
9.6% sodium metrizoate (density 1.077 g/ml, osmolality 280
mOsm). Cells were stimulated with anti-CD3 (2.5 ug/ml) and
anti-CD28 (1 ug/ml) antibodies for 72 hours. IL23R cell surface
cell surface expression was analyzed by flow cytometry using
biotinylated IL23R antibody in combination with streptavidin-PE
(eBioscience).
Cell viability Assay
T cells were plated in 96-well plates in triplicates at 5610
5 cells
per well. IL-23 was added to a final concentration of 100 nM and
a 1:4 dilution series was established. After 72 h of stimulation cells
were analyzed by the CellTiter-Glow Luminescent Cell Viability
Assay according to the instructions of the manufacturer (Promega
Corp). All experiments were performed in triplicate wells.
Proliferation Assay
T cells were plated in 96-well plates in triplicates at 5610
5 cells
per well. IL-23 was added to a final concentration of 100 nM and
a 1:2 dilution series was established. After 72 h of stimulation cells
were analyzed by a 16-h pulse with 1 mCi/well [
3H] thymidine
(Amersham Biosciences) followed by harvesting using a 96-well
plate harvester and counting by liquid scintillation. All experi-
ments were performed in triplicate wells.
Flow cytometry
All data were collected on FacsCalibur and LSR II instruments
(BD Biosciences) and analyzed using FlowJo software (Tree Star).
Figure 6. A summary of the results obtained in this study using genotype-selectable normal donors is depicted. IL23R
Q381 donors had
a significant decrease in IL23R positive T cells, leading to the decreased IL-23 induced STAT3 phosphorylation. Decreased STAT3 signaling in T cells
like TH17 might modulate the extent and duration of the response in the host, leading to decreased secretion of proinflamatory cytokines such as IL-
17 and IL-22 in the gut, explaining the protective effect of R381Q variant in CD and other autoimmune disorders.
doi:10.1371/journal.pone.0025038.g006
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S1, and antibodies were used according to the instructions of the
manufacturer unless otherwise indicated.
IL23R cell surface expression
T cells were stained with biotinylated IL23R antibody 20G3.4
in combination with streptavidin-PE (eBioscience). Isotype control
antibodies were used as negative controls (BD biosciences).
STAT phosphorylation
Flow cytometric analyses of STAT phosphorylation were
performed as previously described [43,44]. Briefly, T cells were
starved overnight in Yssel’s medium supplemented with mono-
clonal anti-human IL-2 antibody to neutralize IL-2. Cells were
stimulated with 10 ng/ml of rhIL-23 or 10 ng/ml of rhIL-6 or
1000 IU/ml of IL-2 and incubated at 37uC for 15 min. Cells were
fixed, permeabilized and stained with phospho-STAT3, phospho-
STAT1 and phospho-STAT5 specific antibodies to detect
activated STAT3, STAT1 and STAT5, respectively.
Whole blood was stimulated with 10 ng/ml of IL-23 or 10 ng/
ml of rhIL-6 and incubated at 37uC for 15 min, fixed and lysed to
halt signaling and lyse red blood cells. Cells were permeabilized
and stained with phospho-STAT3 specific antibodies to detect
activated STAT3.
Intracellular cytokine staining (ICS)
Intracellular staining was done as previously described [45].
Briefly, T cells were stimulated either with Dynabeads CD3/
CD28 T Cell Expander (Invitrogen) (bead:cell ratio=1:10) or with
10 ng/ml PMA plus 500 ng/ml ionomycin (Sigma). After 3 hrs,
BD Golgi Plug with brefeldin A (BD Biosciences) was added to
block secretion. After an additional 3 hrs, T cells were stained with
green live/dead dye (Invitrogen). Cells were fixed in 3%
paraformaldehyde and permeabilized with Perm/Wash buffer
(BD Biosciences). Permeabilized T cells were stained with anti-
hIFN-g, anti-hIL-17, anti-hIL-10, anti-hIL-22 or isotype control
antibodies (BD Biosciences).
Real-time quantitative RT-PCR
Total RNA was extracted from freshly isolated PBMCs of
IL23R
R381 and IL23R
Q381 positive donors using RNeasy Micro
kit (Qiagen). High-Capacity cDNA Archive kit (Applied Biosys-
tems) was used for cDNA synthesis. Transcripts were quantified by
real-time quantitative PCR on an ABI PRISM 7900 sequence
detector (Applied Biosystems) with Applied Biosystems prede-
signed TaqMan Gene Expression Assays. The following probes
were used: RORC (Hs01076112) and IL23R (Hs00332759). For
each sample, mRNA abundance was normalized to the amount of
GAPDH or RPL19 transcripts.
Sequence alignment by CLUSTAL W
IL23R protein sequences from all the species available in
Genbank were aligned with Clustal W in FASTA format (http://
www.ebi.ac.uk/clustalw/).
Statistical analyses
Statistical analyses were performed by the Mann-Whitney test
using R and Graph Pad Prism software was used to calculate
standard deviation. P,0.05 considered statistically significant.
Supporting Information
Figure S1 The specificity of anti-IL23R antibody is demon-
strated using BaF3 cells retrovirally transduced with IL23R
R381.
Representative analysis by flow cytometry show IL23R surface
expression on non-permeabilized transduced BaF3 cells. Isotype
control is indicated by gray shading, non-transformed BaF3 cells
by a red line and IL23R
R381 by a blue line.
(TIF)
Figure S2 Untransformed polyclonal IL23R
Q381 positive T cell
have comparable cell viability and proliferation rates to IL23R
R381
cells. The mean percent (n=4) of representative donors (A) cell
viability and (B) proliferation rates after stimulation with IL-23 for
72 h. Data are representative examples of at least three
independent experiments.
(TIF)
Figure S3 Cytokine levels are comparable in IL23R
Q381 and
IL23R
R381 positive donors. ICS of cytokine production by PBMCs
stimulated with anti-CD3/ CD28 dynabeads (A) representative
donors for IL-22 and IL-17 and (B) IL-10 and INF-g (C) four
donors per group is shown. Data are representative examples of at
least three independent experiments. The Mann-Whitney test was
used to calculate the p value.
(TIF)
Table S1 List of anti-human antibodies used in this study.
(DOCX)
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